Akcea Therapeutics Inc (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals Inc, has named Kia Motesharei, PhD as its new senior vice president of Business Development & Corporate Strategy, it was reported on Tuesday.
In the new role, Dr Motesharei is to manage business development activities at Akcea and will continue to improve the corporate strategy in collaboration with the Akcea leadership team.
Dr Motesharei has over 20 years of business and corporate development and strategy experience with multinational companies. Prior to joining Akcea Therapeutics, Dr Motesharei served Merck KGaA for six-years, where he most recently served as vice president and global head of Licensing and Business Development, Neurology & Immunology. He has also held the positions of vice president of Business Development & Alliance Management at Dyax Corp, chief business Officer at Genfit and vice president of Corporate Development at ActivX.
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business